Ajinomoto Co., Ltd.

Ea Pharma Co., Ltd.

Misato Noguchi

Shunsuke Kageyama

Itsuya Tanabe

Takashi Yamamoto

Masayuki Sugiki

Munetaka Tokumasu

Koichi Fujita

Yoichiro Shima

Ayatoshi Andou

Akira Nakayama

Tamotsu Suzuki

Yasuhiro Tanaka

Tatsuya Okuzumi

Tadakiyo Nakagawa

Kazuyuki Sagi

Noriyasu Kataoka

Tatsuhiro Yamada

Hajime Ito

Yoriko Yamamoto

Ayatoshi Ando

Toshihiko Sugiura

Kenji Shinkai

Nobuhiko Hayakawa

Ryohei Yokoyama

Kazuyuki Ubukata

Agung Eviryanti

Masatsugu Noguchi

Koji Ohsumi

Naoyuki Fukuchi

Akira Chiba

Sayaka Asari

Satoshi Iwayama

Wataru Miyanaga

Kanna Kuribayashi

Yuki Saitou

Atsushi Tsuruta

Shunsuke Fukuda

Chiori Ijichi

Hirokazu Ueno

Tomoko Miyazawa

Kana Iwasaki

Yui Yamaura

Ryuta Takashita

Yuka Kataba

Hiroyuki Eda

Naoko Oomuta

Yuko Iida

Aya Kirihara

Tarou Nakamura

Manami Shuto

Mizuki Kawahira

Mizuki Dohi

Provided is a compound having &#x3b1;4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where Rto R, e to h, D, and B represent those as described in the specification.

Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity

Sulfonamide compounds of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent &#x3b1;4 integrin-inhibitory action. The compounds have formulae represented by: 

Sulfonamide derivative and medicinal use thereof

The present invention has searched for a variety of compounds which show IL-12/IL-23 production-inhibitory activities and herein provides a pharmaceutical composition and an agent for preventing or treating IL-12/IL-23 excess production-related diseases, which comprise the compound.

Pyrazolo-pyrimidine compounds

Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to &#x3b1;4 integrin. They are used as therapeutic agents for various diseases concerning &#x3b1;4 integrin.

Phenylalanine derivatives

Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

Azole compound

Growing community of inventors

Kawasaki, Japan

Misato Noguchi